Back to search

Article

The JAK1/3 inhibitor tofacitinib regulates Th cell profiles and humoral immune responses in myasthenia gravis

2023-08-18

Abstract excerpt

<h4>Background: </h4> Tofacitinib, a first-generation Janus kinase (JAK) 1/3 inhibitor, is widely used in the treatment of ulcerative colitis and rheumatoid arthritis. However, its role in myasthenia gravis (MG) has not yet been clearly explored. Methods Here, we investigated the effects of tofacitinib on experimental autoimmune myasthenia gravis (EAMG) in vivo and in vitro. Besides, the effects of tofacitinib we...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
eec5196d-e6b1-55d7-a16c-f2592af8ea96
DOI
10.21203/rs.3.rs-3260381/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The JAK1/3 inhibitor tofacitinib regulates Th cell profiles and humoral immune responses in myasthenia gravisDOI 10.21203/rs.3.rs-3260381/v1
JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)Semantic proximity
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity
JAK signaling was involved in the pathogenesis of Polymyalgia RheumaticaSemantic proximity
Elevated TRAF 6 Expression in Peripheral B Cells Is Associated with Disease Progression in Myasthenia GravisSemantic proximity
Epigenetic dysregulation of Th2 cytokine genes in MuSK myasthenia gravis and its modulation by immunosuppressive therapySemantic proximity
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritisSemantic proximity
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disordersSemantic proximity
Upadacitinib: Mechanism of action, clinical, and translational scienceSemantic proximity
Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravisSemantic proximity
Spotlight on MuSK Positive Myasthenia Gravis: Clinical Characteristics, Treatment and OutcomesSemantic proximity
JAK/STAT Inhibition Reprograms T Cell Activation and Metabolism in Inflammatory Arthritis PatientsSemantic proximity
JAK inhibitors ∼ overview∼Semantic proximity
Select a neighboring publication to make it the new centre.